Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

"Multi-enzyme-targeted" immunochemotherapy: a salvage therapy protocol.

H O Klein1, G Demir

  • 1University of Cologne, Germany. H-O.Klein@uni-koeln.de

Anticancer Research
|January 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A rare ocular manifestation of trichothiodystrophy: Focal retinal dystrophy.

Journal francais d'ophtalmologie·2021
Same author

Effect of keratorefractive surgery on choroidal thickness in anisometropic amblyopia.

Journal francais d'ophtalmologie·2020
Same author

An alternative approach for the management of a loose single running penetrating keratoplasty suture.

Journal francais d'ophtalmologie·2020
Same author

Validity of ocular trauma score in open globe injury patients from Turkey.

Journal francais d'ophtalmologie·2020
Same author

Manual ability and upper limb performance in nonambulatory stage of Duchenne muscular dystrophy.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2020
Same author

Rate of hypotony and intraocular pressure fluctuation immediately after intravitreal dexamethasone implantation in vitrectomized eyes.

Journal francais d'ophtalmologie·2020
Same journal

Corrigendum.

Anticancer research·2026
Same journal

Geographic Variation in Stage at Diagnosis of Skin Cancer in the United States: A National Cancer Database Analysis.

Anticancer research·2026
Same journal

Anti-tumor Effects of Loureirin A Treatment in Colorectal Cancer Cells <i>via</i> Inhibition of AKT Phosphorylation.

Anticancer research·2026
Same journal

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same journal

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.

Anticancer research·2026
Same journal

Geographic Disparities in Socioeconomic Factors and Advanced-stage Presentation in Rectosigmoid Cancer: A National Cancer Database Analysis.

Anticancer research·2026
See all related articles

This study explored a novel cancer therapy targeting purine and pyrimidine pathways in tumor cells. The protocol showed promising results with low toxicity and notable complete and partial responses in patients with various cancers.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Human tumor cells exhibit significantly elevated activity in purine and pyrimidine de novo and salvage pathways.
  • This metabolic characteristic presents a potential therapeutic target for cancer treatment.

Purpose of the Study:

  • To evaluate a novel cancer therapy protocol designed to exploit the heightened purine and pyrimidine metabolic activity in tumor cells.
  • To assess the efficacy and toxicity of this multi-agent treatment in cancer patients.

Main Methods:

  • Administration of antimetabolites (MTX, 5-FU, dFdC, AZT) targeting key enzymes.
  • Inhibition of macromolecule synthesis with vindesine and ifosfamide.
  • Impairment of DNA repair with hydroxyurea and topotecan, and DNA transcription blockade with actinomycin.

Related Experiment Videos

  • Use of interferon-alpha, interferon-gamma, and interleukin-2 as immunomodulators.

    • Main Results:

    • 47 patients with a median age of 61.5 years and Karnowsky score of 85% were treated in an outpatient setting.
    • The therapy demonstrated low general toxicity, with transient reductions in leucocytes, platelets, and monocytes.
    • Observed outcomes included 3 complete clinical responses (CR), 22 partial responses (PR), and 9 progressive diseases (PD).
    • CR rates were 1/4 for kidney, 1/1 for bladder, and 1/5 for breast cancer.

    Conclusions:

    • The developed therapy protocol, targeting specific metabolic pathways in human tumor cells, is feasible and shows encouraging response rates.
    • The observed low toxicity profile supports its potential for outpatient administration.
    • Further investigation is warranted to optimize this multi-agent approach for broader cancer indications.